8 Biotech Stocks With Clinical Trial Outcomes In April

The market-moving nature of clinical trial results is due to the fact that only a small proportion of drugs that move from pre-clinical trials or animal testing stage advance successfully through the three phases of clinical trials. FDA estimates put the percentage of drugs that move out of the Phase 3 trials into the next stage at 25-30 percent of the total number of candidates entering Phase 1 trials.

Here are a few companies scheduled to release trial results in the first half of April.

1. Can Selecta's Select Cohort Data on Its Gout Candidate Get it Moving

  • Company: Selecta Biosciences Inc SELB
  • Product Candidate: SEL-212
  • Indication: Tophaceous gout
  • Trial: Phase 2 data from cohorts receiving three monthly doses of SEL-212- pegsiticase combo followed by two monthly doses of pegsiticase alone
  • Date Expected: April 9 or 10 at the Panamerican League of Associations for Rheumatology Congress

Selecta's lead product candidate SEL-212, a therapeutic enzyme, is touted to be the first biologic treatment for gout, a condition in which defective metabolism of uric acid causes arthritis, especially in the smaller bones of the feet.

Related Link: Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

2. Novartis to Present Abstract of Phase 3 Study On Psoriatic Arthritis Candidate

  • Company: Novartis AG (ADR) NVS
  • Product Candidate: AIN457 (Cosentyx)
  • Indication: Psoriatic arthritis
  • Trial: Abstract of 52-week results from the Phase 3 study (NCT02294227 FUTURE 4) to be submitted to the PANLAR Congress scheduled between April 7-10
  • Date Expected: April 7-10

Novartis' Cosentyx is a fully human interlukin-17A inhibitor, which showed long-term efficacy in treating moderate-to-severe psoriasis, psoriatic arthritis and ankylosing arthritis. It was first approved in 2015 to treat moderate-to-severe plaque psoriasis.

3. Can Galectin Churn Out Better Tidings On its NASH Candidate

  • Company: Galectin Therapeutics Inc. Common Stock GALT
  • Product Candidate: GR-MD-02
  • Indication: Non-alcoholic steatohepatitis (NASH) with cirrhosis
  • Trial: Phase 2b
  • Date Expected: April 14

Galectin's treatment candidate for NASH, which is an acute form of non-alcoholic fatty liver disease, suffered a setback in December, when top-line data from a Phase 2b study did not meet primary endpoint across all patients. However, the company noted improvement in subgroups.

The results of the Phase 2b study is to be presented as a late breaker at the EASL congress.

Data from a Phase 2a study released in September 2017 showed the study did not meet the primary and secondary endpoints.

4. OncoSec to Release Early-stage Results of Breast Cancer Treatment

  • Company: OncoSec Medical Inc ONCS
  • Product Candidate: ImmunoPulse IL-12
  • Indication: Triple Negative Breast Cancer, or TNBC
  • Trial: Phase I data to be presented at the American Association For Cancer Research, or AACR
  • Date Expected: April 15

ImmunoPulse focuses on delivery of DNA-based interlukin-12, a naturally occurring protein with immune-stimulating functions. It is currently being tested for TNBC and metastatic melanoma.

5. ArQule To Present On Oncology Treatment Candidate

  • Company: ArQule, Inc. ARQL
  • Product Candidate: Miransertib (ARQ 092)
  • Indication: Solid Tumors (to treat patients with lymphoma, endometrial cancer and AKT1 E17K mutations)
  • Trial: Phase 1b at the AACR
  • Date Expected: April 15

Miransertib is an orally available, selective, pan-AKT inhibitor that likely inhibits AKT1,2 and 3 isoforms.

6. Blueprint Looking to Print Solid Early Results

  • Company: Blueprint Medicines Corp BPMC
  • Product Candidate: BLU-667
  • Indication: RET-altered solid tumors (to treat patients with advanced non-small cell lung cancer, advanced thyroid cancer and other advanced solid tumors)
  • Trial: Initial Phase 1 data
  • Date Expected: April 15

The Phase 1 study was started in March 2017.

Related Link: Mesoblast's Delayed Launches, Teva Split Turn Credit Suisse Bearish

7. Toca Would Let The Results Talk

  • Company: Tocagen Inc TOCA
  • Product Candidate: Toca 511 - Toca 6
  • Indication: Metastatic solid tumors (colorectal cancer, renal cell carcinoma, melanoma, pancreatic cancer and lung & breast cancer)
  • Trial: Phase 1b
  • Date Expected: April 16

8. Tesaro Also to Release Results For Advanced Solid Tumor Candidate

  • Company: TESARO Inc TSRO
  • Product Candidate: TSR-042
  • Indication: Advanced solid Tumors, including metastatic endometrial cancer
  • Trial: Phase 1 (study dubbed GARNET)
  • Date Expected: April 16
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechPreviewsTop StoriesTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!